AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.
China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...
ing Xie is a lecturer at the School of Marxism Studies, Zhejiang University of Finance and Economics, Hangzhou, Zhejiang, China. In the past two decades, China has made big advances in scientific ...
China’s rise in science has been even more dramatic than its rapid economic development. China and the United States currently spend far more on research and development and publish significantly more ...
China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time regulators take to review clinical trials. In a draft policy posted (Chinese ...
Out of five critical tech sectors, "China has the most immediate opportunity to overtake the United States in biotechnology," the Harvard Belfer Center said in a new report. Just as China is ...
The recently concluded Fourth Plenum Session of the Communist Party of China approved the draft proposal for the 15th Five-Year Plan, setting the strategic direction for China’s next stage of ...
As the International Space Station nears retirement, a bipartisan senatorial group proposed a National Institute for Space Research for U.S. microgravity research. When you purchase through links on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results